We are pioneering a new class of biologics we call endobody vaccines that are fully synthetic and train the body’s immune system to safely and efficiently treat and prevent neurodegenerative disease.
We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics leveraging the industry’s leading endobody vaccine technology. Our proprietary platform technologies have successfully commercialized over 3 billion doses to date in multiple indications and launched 1 of only a handful of licensed vaccines against an endogenous host protein in the world.
We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of patients and families affected by Alzheimer’s, Parkinson’s, ALS and other neurological diseases. We envision a world where the incidence of Alzheimer’s is cut in half by 2050 and where neurodegenerative diseases are prophylactically eradicated from the world.